IP Library Granted Patent US 9,422,318
Granted Patent B2
US 9,422,318 · App. 14/813,615 · Granted Aug 23, 2016

Epoxyeicosatrienoic acid analogs and methods of making and using the same

Inventors: John David Imig (Pewaukee, WI); William B. Campbell (Whitefish Bay, WI); John Russell Falck (University Park, TX)
Assignees: The Medical College of Wisconsin, Inc.; The Board of Regents of the University of Texas System
C07F9/40C07C233/46C07C233/47C07C233/56C07C237/22C07C275/20C07C309/15C07C311/18C07C311/19C07C311/51C07C317/28C07C323/44C07D249/12C07D257/04C07D271/06C07D271/07C07D277/34C07D277/593C07D277/82C07D285/08C07D291/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,422,318
App. No.
14/813,615
Granted
Aug 23, 2016
Kind
B2
Abstract

Compounds and compositions comprising epoxyeicosatrienoic acid (EET) analogs that act as EET agonists and are useful as medications in the treatment of drug-induced nephrotoxicity, hypertension and other related conditions. Methods of making and using the compounds and compositions are further described.

Claims (7)

1. A compound selected from the group consisting of

2. A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

3. A method of reducing hypertension in a subject, comprising administering to a subject a therapeutically effective amount of a compound according to claim 1 , wherein hypertension in said subject is reduced.

4. A method of reducing nephrotoxicity in a subject, comprising administering to a subject a therapeutically effective amount of a compound according to claim 1 , wherein nephrotoxicity in said subject is reduced.

5. The method of claim 4 , wherein the nephrotoxicity is drug-induced.

6. The method of claim 4 , wherein the nephrotoxicity is cisplatin-induced.

7. A method of reducing cisplatin nephrotoxicity in a subject, comprising administering to a subject a therapeutically effective amount of a compound according to claim 1 , wherein cisplatin nephrotoxicity in said subject is reduced.

Assignments (4)
CONFIRMATORY LICENSE Recorded Dec 6, 2018
From: MEDICAL COLLEGE OF WISCONSIN
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 048802/0075 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2016
From: MCW RESEARCH FOUNDATION, INC.
To: THE MEDICAL COLLEGE OF WISCONSIN, INC.
Reel/Frame 039892/0801 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2016
From: FALCK, JOHN RUSSELL
To: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 039804/0545 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2016
From: CAMPBELL, WILLIAM B.; IMIG, JOHN DAVID
To: MCW RESEARCH FOUNDATION, INC.
Reel/Frame 039804/0591 →
Continuity (4)
Division 14009658
Provisional Application 61608361 · Mar 8, 2012
Provisional Application 61472410 · Apr 6, 2011
Related Publication 20150336916A1 · Nov 26, 2015